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Introduction
Cancer has been the leading cause of death in Korea since 1983 [1] and
has drawn much public health attention. More than 180,000 new cancer
cases are diagnosed annually in Korea, and one of four deaths results from
cancer [2,3]. This study provides an overview of the nationwide cancer
statistics, including the incidence, mortality, prevalence, survival rates,
and their trends in Korea.
1. Data sources
The Korean Ministry of Health and Welfare, initiated a nationwide hos-
pital-based cancer registry called the Korea Central Cancer Registry
(KCCR) as early as 1980. The registry collected 80-90% of cancer cases
annually from more than 180 training hospitals throughout the country.
In 1999, the KCCR expanded cancer registration to cover the entire pop-
ulation under the Population-Based Regional Cancer Registry program.
Details of the history, objectives, and activities of the KCCR have been
documented [4]. Incidence data from 1999 to 2009 were obtained from
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Purpose
This study overviews nationwide cancer statistics, including incidence, mortality, survival, and
prevalence, and their trends in Korea based on 2009 cancer incidence data.
Materials and Methods
Incidence data from 1993-2009 were obtained from the Korea National Cancer Incidence Data-
base, and vital status was followed through 31 December 2010. Mortality data from 1983-2009
were obtained from Statistics Korea. Crude rates and age-standardized rates for incidence, mor-
tality, and prevalence; and relative survival were calculated.
Results
In total, 192,561 cancer cases and 69,780 cancer deaths were observed during 2009, and 808,503
10-year cancer prevalent cases occurred in Korea as of 1 January 2010. The incidence rate for
all cancers combined showed an annual increase of 3.3% from 1999 to 2009. 
Conclusion
Stomach, liver and cervical cancers have been decreasing and thyroid, breast and colorectal
cancers have been increasing at large. In particular, in 2009, colorectal cancer became the third
most common cancer in females and for the first time ranked higher than stomach cancer, which
had been the long-standing common cancer in Korea. While overall cancer incidence has been
rapidly increasing in Korea, age-standardized cancer mortality rates have been declining since
2002, and cancer survival has been improving.
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pleteness of incidence data for 2009 was 97.2%, as determined by the
Ajiki method [5].
Cancer cases were classified according to the International Classifica-
tion of Diseases for Oncology, 3rd edition [6] and converted according to
the International Classification of Diseases, 10th edition (ICD-10) [7].
The survival analysis used 1,804,388 cancer cases first diagnosed during
1993-2009 from the KNCI DB, and followed vital status through 31 De-
cember 2010.
Mortality data from 1983-2009 were obtained from Statistics Korea
[1]. The cause of death was coded and classified according to the ICD-
10. Population data were also obtained from Statistics Korea using the
resident registration population on July 1 of specified years.
Analysis
Crude rates (CRs) and age-specific rates of cancer incidence and mor-
tality were calculated. Age-standardized rates (ASRs) were determined
using the World Health Organization world standard population [8]. The
cumulative risks of cancer incidence, which represent the probability of
developing cancer during a lifetime, were also calculated. Changes in the
annual ASRs of cancer incidence were examined by calculating the annual
percentage change over a time period as (exp(b)-1)ￗ100, where bis the
slope of the regression of log ASR for a given calendar year [9].
Prevalence was also estimated to assess the level of cancer burden,
which represents new and pre-existing cancer patients diagnosed during
a given period of time who were still alive on an index date. Using the
cancer incidence database from 2000-2009, we calculated the limited-du-
ration prevalence, such as the 1-, 5-, and 10-year prevalence. For example,
the 10-year prevalence was calculated from the number of people alive
on 1 January 2010 who had been diagnosed with cancer within the pre-
vious 10 years. We applied the counting method using SEER*Stat soft-
ware [10] to calculate the number of cases while adjusting for patients
lost to follow-up [9].
The survival duration of each case was determined as the interval be-
tween the date of initial diagnosis and the date of death, date of loss to fol-
low-up, or closing date for follow-up. Observed survival rates were
calculated using the life table method and relative survival rates were ex-
amined with the Ederer II method [11] using an algorithm written in SAS
by Dickman [12], with some minor modifications.
Selected Findings
1. Incidence
Table 1 presents the overall number of cancer incident cases, deaths,
and prevalent cases during 2009 in Korea by sex and cancer site. In 2009,
192,561 cancer incident cases and 69,780 deaths were observed in Korea.
As of 1 January 2010, 808,503 10-year cancer prevalent cases were ob-
served in Korea. The cumulative risk for developing cancer during a life-
time was 37.9% for men and 32.7% for women in 2009.
Table 2 shows the cancer incidence rates by sex in 2009. The CRs of
all sites combined in 2009 were 398.9 and 376.7 per 100,000 in males
and females, respectively. The ASRs of all sites combined were 325.5 and
259.3 per 100,000 in males and females, respectively. In males, the five
leading primary cancer sites were the stomach (CR, 80.2; ASR, 64.5),
colon and rectum (CR, 60.6; ASR, 49.0), lung (CR, 56.4; ASR, 46.8),
liver (CR, 47.9; ASR, 37.7), and prostate (CR, 29.6; ASR, 24.8), account-
ing for 68.8% of all newly diagnosed cancers in 2009. In females, the
most common cancer sites were the thyroid (CR, 108.2; ASR, 79.6), breast
(CR, 54.1; ASR, 38.3), colon and rectum (CR, 40.0; ASR, 25.9), stomach
(CR, 39.4; ASR, 25.5), lung (CR, 22.8; ASR, 13.9), and liver (CR, 16.2;
ASR, 10.4), accounting for 74.6% of all newly diagnosed cancers. Thy-
roid cancer alone accounted for 28.7% (n=26,815) of incident cases in
females in 2009.
2. Mortality
In total, 69,780 cancer deaths were reported in Korea during 2009, ac-
counting for 28.3% of all deaths (Table 3). In 2009, the CRs of all sites
combined were 176.3 and 104.7 per 100,000 for males and females, re-
spectively. The ASRs of all sites combined were 146.7 and 62.9 per
100,000 for males and females, respectively. Cancers of the lung, liver,
stomach, and colon and rectum were the most common fatal cancers, ac-
counting for about 62.1% of all cancer deaths in 2009 (Table 4).
In males, the five leading fatal primary cancer sites in 2009 were the
lung (CR, 43.8; ASR, 36.6), liver (CR, 33.9; ASR, 27.1), stomach (CR,
26.9; ASR, 22.3), colon and rectum (CR, 15.8; ASR, 13.2), and pancreas
(CR, 9.0; ASR, 7.4). In females, lung cancer mortality (CR, 16.3; ASR,
9.2) increased gradually and was the most fatal cancer site in 2009, fol-
lowed by the stomach (CR, 13.9; ASR, 8.1), colon and rectum (CR, 12.6;
ASR, 7.3), liver (CR, 11.4; ASR, 6.9), and breast (CR, 7.6; ASR, 5.2).
3. Trends in cancer incidence
Tables 5-7 present the cancer incidence rates during 1999-2009 in
Korea for all sites combined and for selected cancer sites. The incidence
rate for all sites combined increased by 3.3% annually (1.6% in males,
5.3% in females) from 1999 to 2009. The rapid increase in cancer inci-
dence is also illustrated in Fig. 1.
As shown in Fig. 2, the incidence rates have continued to increase for
colorectal and thyroid cancers in both sexes, along with breast cancer in
females and prostate cancer in males. In contrast, the incidences of liver
cancer in both sexes and cervical cancer in females have decreased. Stom-
ach cancer incidence rates remained the same in males and females. One
notable aspect was the sharp increase (25.1% annually) in the incidence
of thyroid cancer in females. Improvements in the sensitivity of diagnostic
Cancer Res Treat. 2012;44(1):11-24
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Table 3. Ten leading causes of death during 2009 in Korea
Rank Cause of death No. of deaths Percent of all deaths
Age-standardized 
death rates/100,000a)
All causes 246,942 100.0 349.5
1 Cancer 69,780 28.3 97.8
2 Cerebrovascular disease 25,838 10.5 34.2
3 Heart disease 22,347 9.0 30.3
4 Intentional self harm (suicide) 15,413 6.2 23.8
5 Diabetes mellitus 9,757 4.0 13.1
6 Transport accidents 7,147 2.9 11.5
7 Chronic lower respiratory diseases 6,914 2.8 9.0
8 Disease of liver 6,868 2.8 9.9
9 Pneumonia 6,324 2.6 8.4
10 Hypertensive diseases 4,749 1.9 6.3
Others 71,805 29.1 105.3
Source: Mortality Data, 2009, Korea National Statistical Office. a)Age adjusted to the World Health Organization world standard population.
Table 2. Crude and age-standardized cancer incidence rates by gender during 2009 in Korea
CNS, central nervous system. a)Age adjusted to the World Health Organization world standard population, b) Includes gallbladder and other/un-
specified parts of the biliary tract.
Crude incidence rates/100,000 Age-standardized incidence rates/100,000a)
Sites
Both genders Male Female Both genders Male Female
All sites 387.8 398.9 376.7 282.0 325.5 259.3
Lip, oral cavity, and pharynx 5.1 7.5 2.6 3.7 6.0 1.8
Esophagus 4.3 7.9 0.6 3.1 6.5 0.4
Stomach 59.9 80.2 39.4 43.0 64.5 25.5
Colon and rectum 50.3 60.6 40.0 36.2 49.0 25.9
Liver 32.1 47.9 16.2 23.2 37.7 10.4
Gallbladderb) 9.6 9.6 9.7 6.7 8.0 5.7
Pancreas 8.9 9.8 8.0 6.2 8.0 4.8
Larynx 2.3 4.3 0.3 1.7 3.6 0.2
Lung 39.6 56.4 22.8 27.8 46.8 13.9
Breast 27.1 0.2 54.1 19.4 0.2 38.3
Cervix uteri 7.5 - 15.1 5.4 - 10.5
Corpus uteri 3.5 - 7.0 2.6 - 5.0
Ovary 3.6 - 7.2 2.7 - 5.2
Prostate 14.8 29.6 - 10.4 24.8 -
Testis 0.4 0.8 - 0.4 0.8 -
Kidney 6.9 9.4 4.5 5.1 7.5 3.1
Bladder 6.5 10.3 2.6 4.5 8.5 1.5
Brain and CNS 3.3 3.6 3.1 2.9 3.4 2.5
Thyroid 64.4 20.8 108.2 47.5 15.4 79.6
Hodgkin lymphoma 0.4 0.6 0.3 0.4 0.5 0.3
Non-Hodgkin lymphoma 7.8 8.7 6.9 6.0 7.3 5.0
Multiple myeloma 2.1 2.3 1.8 1.5 1.9 1.2
Leukemia 5.4 6.0 4.8 5.0 5.9 4.2
Other and ill-defined 21.9 22.5 21.3 16.5 19.3 14.3
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techniques for thyroid cancer, such as the advent of ultrasound and fine-
needle aspiration, have enabled the detection of subclinical disease. There-
fore,  the  increased  incidence  of  thyroid  cancer  may  reflect  the
identification of previously undetected disease with these improved di-
agnostic techniques, rather than a true increase in the occurrence of thyroid
cancer [13,14]. Furthermore, due to the construction of a 1999-2009
KNCI DB, the completeness of the Korea cancer registry data has im-
proved gradually, and this may have contributed, in part, to the gradual
overall increases in cancer incidence, particularly among elderly patients.
In particular, in 2009, colorectal cancer became the third most common
cancer in females and for the first time ranked higher than stomach cancer,
which had been the long-standing common cancer in Korea.
4. Age-specific incidence rates for selected cancer sites
Table 8 presents the most common cancer sites by sex and age group
in 2009. Leukemia and thyroid cancer were the most common forms in
both sexes for ages 0-14 and 15-34 years, respectively. For males, stomach
cancer was the most common in 35-64-year-olds, while lung cancer was
Table 4. Crude and age-standardized cancer mortality rates by gender during 2009 in Korea
CNS, central nervous system. a)Age adjusted to the World Health Organization world standard population, b) Includes gallbladder and other/un-
specified parts of the biliary tract.
Crude incidence rates/100,000 Age-standardized incidence rates/100,000a)
Sites
Both genders Male Female Both genders Male Female
All sites 140.5 176.3 104.7 97.8 146.7 62.9
Lip, oral cavity, and pharynx 2.0 3.1 0.8 1.4 2.5 0.5
Esophagus 2.8 5.2 0.4 2.0 4.3 0.2
Stomach 20.4 26.9 13.9 14.0 22.3 8.1
Colon and rectum 14.2 15.8 12.6 9.7 13.2 7.3
Liver 22.6 33.9 11.4 16.2 27.1 6.9
Gallbladderb) 7.3 7.1 7.4 4.9 6.0 4.1
Pancreas 8.2 9.0 7.4 5.6 7.4 4.2
Larynx 0.9 1.5 0.2 0.6 1.3 0.1
Lung 30.0 43.8 16.3 20.5 36.6 9.2
Breast 3.8 0.1 7.6 2.7 0.1 5.2
Cervix uteri 1.9 - 3.8 1.3 - 2.4
Corpus uteri 0.4 - 0.9 0.3 - 0.6
Ovary 1.7 - 3.4 1.2 - 2.3
Prostate 2.5 5.0 - 1.6 4.6 -
Testis 0.0 0.1 - 0.0 0.1 -
Kidney 1.5 2.0 1.0 1.0 1.6 0.6
Bladder 1.9 2.9 1.0 1.3 2.5 0.5
Brain and CNS 2.1 2.2 2.0 1.7 1.9 1.5
Thyroid 0.7 0.4 1.0 0.5 0.4 0.5
Hodgkin lymphoma 0.1 0.1 0.1 0.1 0.1 0.0
Non-Hodgkin lymphoma 2.7 3.1 2.3 1.9 2.6 1.4
Multiple myeloma 1.4 1.5 1.3 1.0 1.2 0.8
Leukemia 3.1 3.4 2.8 2.5 3.0 2.1
Other and ill-defined 8.1 9.2 7.0 5.8 7.8 4.3
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Fig. 1. Annual age-standardized cancer incidence and death rates for
all sites by sex during 1983-2009 in Korea. Age standardization was
based on the World Health Organization world standard population.
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Fig. 2. Trends in age-standardized cancer incidence for selected cancers by sex during 1999-2009 in Korea. Age standardization was based on the
World Health Organization world standard population. (A) Male. (B) Female.
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Fig. 3. Age-specific incidence rates for major cancers during 2009 in Korea. (A) Male. (B) Female.
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more frequent for patients aged ≥ 65 years. Thyroid cancer was the most
common site for middle-aged Korean women (range, 35 to 64 years), and
colorectal cancer was the most common among older women (range, ≥
65 years).
Fig. 3 shows the age-specific incidence rates for selected cancers in
males and females in 2009. The data show that the incidence of stomach,
lung, liver, and colorectal cancers increased gradually with age. Incidence
rates for breast and thyroid cancers in females were highest in women in
their late 40s and early 50s, respectively, and leveled off thereafter. This
pattern was very different from rates in Western countries [15].
5. Trends in cancer mortality
Figs. 1 and 4 show the trends in cancer deaths for all sites combined
and for selected cancer sites. ASRs of mortality have decreased for all
sites combined in both sexes since 2002. Lung cancer surpassed stomach
cancer as the leading cause of cancer deaths in 1999 and is expected to
account for 21.4% of all cancer deaths in 2009. The ASRs of mortality
due to lung cancer have decreased slightly for men since 2001, but have
increased in women. The ASRs of mortality due to stomach and cervical
cancers have decreased continuously. The mortality rates of these cancers
have also continued to increase along with the significant increases in col-
orectal, prostate, and female breast cancer incidence.
6. Survival rates
Table 9 shows the 5-year relative survivals for four periods of diagnosis:
1993-1995, 1996-2000, 2001-2005, and 2005-2009. Patients with cancer
who were diagnosed in the recent period (2005-2009) had 5-year relative
survival rates of 62.0% for all sites combined in both sexes (53.2% in
males and 71.4% in females). When compared with earlier periods, no-
table improvements were observed in the 5-year relative survival rates for
all sites combined. The observation of higher cancer survival rates in fe-
males than in males may be partly explained by common cancers in fe-
males (e.g., thyroid, breast, and uterine/cervical) that are known to have
relatively good prognoses.
When examined by the year of diagnosis and cancer site, the 5-year
relative survival rates appeared to be higher for most major cancer sites
in patients diagnosed during 2005-2009 compared with 1993-1995, ex-
cept for pancreatic cancer. The greatest improvements were seen in non-
Hodgkin lymphoma, prostate, and stomach cancers, as well as leukemia.
The improving survival rates could be attributable to early detection and
improved treatments [16,17], but this requires further evaluation. A lack
of progress in early detection and treatment could explain the observed
absence of improvement in the survival rate for pancreatic cancer [18].
Table 8. Five major sites of cancer incidence by age group and gender during 2009 in Korea
CNS, central nervous system.
Age group (yr)
Rank
0-14 15-34 35-64 ≥65
Male
1 Leukemia Thyroid Stomach Lung
(5.0) (9.4) (95.8) (451.5)
2 Brain and CNS Stomach Colon and rectum Stomach
(2.4) (3.1) (71.1) (443.9)
3  Non-Hodgkin lymphoma Leukemia Liver Colon and rectum
(1.6) (3.0) (68.1) (340.7)
4 Kidney Colon and rectum Lung Prostate
(0.5) (2.7) (41.8) (268.2)
5 Testis Non-Hodgkin lymphoma Thyroid Liver
(0.4) (2.6) (35.9) (209.2)
Female
1 Leukemia Thyroid Thyroid Colon and rectum
(3.5) (52.1) (192.5) (171.0)
2 Brain and CNS Breast Breast Stomach
(1.7) (10.0) (102.8) (160.5)
3 Non-Hodgkin lymphoma Cervix uteri Stomach Lung
(1.1) (5.3) (42.2) (120.5)
4 Ovary Stomach Colon and rectum Thyroid
(0.8) (4.2) (41.6) (82.1)
5 Kidney, thyroid Colon and rectum Cervix uteri Liver
(0.3) , (0.3) (2.6) (22.0) (76.9)
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7. Prevalence rates
Table 10 shows the 10-year cancer prevalent rates on January 1, 2010
in Korea by sex and cancer site. The 10-year cancer prevalence CRs of
all sites combined were 1,491.4 and 1,765.5 per 100,000 in males and fe-
males, respectively, and the 10-year cancer prevalence ASRs of all sites
combined were 1,218.2 and 1,237.3 per 100,000 in males and females,
respectively. In males, the five leading primary sites of cancer for preva-
lence were the stomach (CR, 389.6; ASR, 312.9), colon and rectum (CR,
275.6; ASR, 223.8), liver (CR, 117.9; ASR, 93.8), prostate (CR, 117.3;
ASR, 99.2), and lung (CR, 102.8; ASR, 84.5), accounting for 67.3% of
all cancer prevalent cases. In females, the most common cancer sites were
the thyroid (CR, 470.4; ASR, 342.6), breast (CR, 349.2; ASR, 247.0),
stomach (CR, 196.4; ASR, 128.5), colon and rectum (CR, 190.4; ASR,
123.4), cervix (CR, 131.5; ASR, 91.0), and lung (CR, 51.4; ASR, 33.3),
accounting for 78.6% of all cancer prevalent cases.
Fig. 5 shows prevalence by time since diagnosis. For all cancers com-
bined, the 1-2-year prevalence represented 36% of the total prevalent
cases. The 1-2-year prevalence as a percentage of the total was highest
for thyroid cancer (20%), followed by stomach (16%) and colorectal
(14%) cancers, which had the high incidence rates and good prognoses.
For all cancers combined, the 2- to 5-year and 5- to 10-year prevalence
constituted 34% and 30% of the total prevalence in both sexes, respec-
tively. The long-term prevalence of lung and liver cancers was relatively
low due to lower survival rates.
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